The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Tyra Biosciences (TYRA) announced that the U.S. FDA cleared its Investigational New Drug application for TYRA-300 allowing the company to ...

Solid Biosciences received clearance from the Food and Drug Administration for an investigational new drug application, the company said Tuesday.

Solid Biosciences (SLDB) announced that the FDA has cleared its investigational new drug, or IND, application for SGT-212 for the treatment of Friedreich’s ataxia, a degenerative disease caused ...

Revidia Therapeutics Inc., a cardiac regenerative medicine company developing first-in-class small molecule drug therapies for heart injury, has announced that it has expanded its leadership team in ...

cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive ...

Solid Biosciences Inc. SLDB announced that the FDA has cleared its investigational new drug (IND) application to begin ...